Nipent pentostatin: Phase II; marketed to treat hairy cell leukemia

In a U.S. Phase II trial of Nipent combined with 1 of 2 doses of cyclophosphamide in 23 patients, 4 had a complete response that lasted a median of 13 months after 6 treatment cycles. Thirteen patient...